IFNAR1 (Interferon alpha/beta receptor 1) variants and mutations
IFNAR1 (also known as Interferon alpha/beta receptor 1) is a human protein-coding gene encoding an interferon alpha/beta receptor 1 protein. Together with IFNAR2, it detects type I interferons and activates JAK-STAT antiviral and immunoregulatory programs. Loss-of-function can impair antiviral defense, while excessive pathway activation contributes to interferon-driven inflammatory disease. This analysis covers 819 IFNAR1 variants and mutations. Of these, 95% have computational variant effect predictions. Disease context includes immunodeficiency 106, susceptibility to viral infections, melanoma, and neoplasm. Example IFNAR1 variants include M2I, M2V, and M2R.
Variant analysis overview
- Gene: IFNAR1
- Protein: Interferon alpha/beta receptor 1
- UniProt accession: P17181
- Organism: Homo sapiens
- Variants analyzed: 819
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 612 unspecified-consequence records; 112 missense variants; 72 synonymous variants; 5 in-frame deletions; 10 frameshift variants; 3 stop-gained variants; 2 splice-region variants; 3 substitution
- Prediction scores: 776 variants have prediction scores (95% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: immunodeficiency 106, susceptibility to viral infections, melanoma, neoplasm, multiple sclerosis, chronic hepatitis B virus infection, chronic hepatitis C virus infection, hepatitis C virus infection, hepatitis B virus infection, systemic lupus erythematosus, acquired polycythemia vera, essential thrombocythemia, hairy cell leukemia.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 4 domains; 16 post-translational modification sites.
- Structural context: 593 variants have structural context.
- PTM context: 27 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable IFNAR1 variants
Examples include M2I, M2V, M2R, V3V, V4A, V4I, V4G, L5P. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M2I (p.Met2Ile), NCI-TCGA TCGA novel, REVEL 0.23, MetaLR 0.32, Variant assessed as somatic; moderate impact.
- M2V (p.Met2Val), TOPMed rs2083112131, MetaLR 0.27, MetaSVM -0.64
- M2R (p.Met2Arg), gnomAD 21-33325060-T-G, REVEL 0.33, MetaLR 0.28
- V3V (p.Val3Val), rs1224222463, gnomAD 21-33325064-C-T, CADD 7.37
- V4A (p.Val4Ala), Ensembl rs2123645149, MetaLR 0.06, MetaSVM -0.91
- V4I (p.Val4Ile), rs2083112232, ClinGen CA410104869, ClinVar RCV003040244, Ensembl rs2083112232, REVEL 0.01, MetaLR 0.11, Uncertain significance, not provided
- V4G (p.Val4Gly), gnomAD 21-33325066-T-G, REVEL 0.05, MetaLR 0.09
- L5P (p.Leu5Pro), Ensembl rs966070127
- L5R (p.Leu5Arg), rs966070127, ClinGen CA410104888, ClinVar RCV002598495, Uncertain significance, not provided
- L5V (p.Leu5Val), gnomAD rs1401132041, REVEL 0.03, MetaLR 0.14
- L5I (p.Leu5Ile), gnomAD 21-33325068-C-A, REVEL 0.07, MetaLR 0.20
- L5F (p.Leu5Phe), gnomAD 21-33325068-C-T, REVEL 0.04, MetaLR 0.20
- L5L (p.Leu5Leu), rs1327744614, gnomAD 21-33325070-C-A, CADD 9.83
- L6P (p.Leu6Pro), rs1261792292, ClinGen CA410104896, ClinVar RCV002033813, ClinVar RCV005854180, REVEL 0.36, MetaLR 0.46, Uncertain significance, not specified; not provided
- L6del (p.Leu6del), rs757724496, gnomAD 21-33325065-GTCC-, CADD 11.30
- L6L (p.Leu6Leu), rs770095813, gnomAD 21-33325071-C-T, CADD 9.87
- L6Q (p.Leu6Gln), gnomAD 21-33325072-T-A, REVEL 0.35, MetaLR 0.46
- G7D (p.Gly7Asp), ESP rs371310065, ExAC rs371310065, TOPMed rs371310065, gnomAD rs371310065, REVEL 0.20, MetaLR 0.21, Uncertain significance, not specified
- G7S (p.Gly7Ser), gnomAD rs1189824203, REVEL 0.27, MetaLR 0.37
- G7G (p.Gly7Gly), rs940699652, gnomAD 21-33325076-C-T, CADD 9.04
- A8E (p.Ala8Glu), NCI-TCGA Cosmic COSV9953, Variant assessed as somatic; moderate impact.
- A8S (p.Ala8Ser), ExAC rs763417814, gnomAD rs763417814, REVEL 0.22, MetaLR 0.39
- A8T (p.Ala8Thr), ExAC rs763417814, gnomAD rs763417814, MetaLR 0.25, MetaSVM -0.67
- A8A (p.Ala8Ala), gnomAD 21-33325079-G-A, CADD 10.10
- T9M (p.Thr9Met), TOPMed rs1487617470, gnomAD rs1487617470, REVEL 0.08, MetaLR 0.21
- T9R (p.Thr9Arg), TOPMed rs1487617470, gnomAD rs1487617470, REVEL 0.26, MetaLR 0.34
- T9A (p.Thr9Ala), gnomAD 21-33325080-A-G, REVEL 0.04, MetaLR 0.15
- T9K (p.Thr9Lys), gnomAD 21-33325081-C-A, REVEL 0.19, MetaLR 0.29
- T9T (p.Thr9Thr), rs766429391, gnomAD 21-33325082-G-A, CADD 9.82
- T10A (p.Thr10Ala), rs751675124, ClinGen CA10006351, ClinVar RCV001920296, ClinVar RCV004043304, REVEL 0.07, MetaLR 0.20, Conflicting interpretations, not provided; not specified
- T10P (p.Thr10Pro), rs1409062242, gnomAD 21-33325081-CG-C, CADD 22.50
- L11P (p.Leu11Pro), ExAC rs767812473, TOPMed rs767812473, gnomAD rs767812473, REVEL 0.41, MetaLR 0.45
- L11V (p.Leu11Val), rs759467737, ClinGen CA10006352, ClinVar RCV001940863, ExAC rs759467737, REVEL 0.06, MetaLR 0.17, Uncertain significance, not provided
- L11L (p.Leu11Leu), gnomAD 21-33325086-C-T, CADD 9.52
- L11I (p.Leu11Ile), gnomAD 21-33325086-C-A, REVEL 0.13, MetaLR 0.33
- V12A (p.Val12Ala), gnomAD 21-33325090-T-C, REVEL 0.21, MetaLR 0.38
- V12V (p.Val12Val), rs752922286, gnomAD 21-33325091-G-A, CADD 9.96
- L13F (p.Leu13Phe), ExAC rs777682349, gnomAD rs777682349, REVEL 0.46, MetaLR 0.58
- L13P (p.Leu13Pro), Ensembl rs976090344, MetaLR 0.60, MetaSVM -0.36
- L13I (p.Leu13Ile), gnomAD 21-33325092-C-A, REVEL 0.35, MetaLR 0.43
- L13L (p.Leu13Leu), rs753896436, gnomAD 21-33325094-C-A, CADD 8.26
- V14A (p.Val14Ala), gnomAD rs1229293322, REVEL 0.44, MetaLR 0.38
- V14del (p.Val14del), gnomAD 21-33325092-CTCG-, CADD 15.80
- V14V (p.Val14Val), gnomAD 21-33325097-C-T, CADD 8.34
- A15S (p.Ala15Ser), gnomAD 21-33325098-G-T, REVEL 0.17, MetaLR 0.36
- A15A (p.Ala15Ala), rs757202886, gnomAD 21-33325100-C-T, CADD 7.82
- V16L (p.Val16Leu), TOPMed rs866787077, gnomAD rs866787077, REVEL 0.08, MetaLR 0.14, Uncertain significance
- V16M (p.Val16Met), rs866787077, ClinGen CA320129914, ClinVar RCV001989289, ClinVar RCV005585064, REVEL 0.10, MetaLR 0.26, Uncertain significance, not provided; not specified
- V16A (p.Val16Ala), gnomAD 21-33325102-T-C, REVEL 0.07, MetaLR 0.21
- A17S (p.Ala17Ser), TOPMed rs2083113169, gnomAD rs2083113169, REVEL 0.12, MetaLR 0.26
- A17V (p.Ala17Val), rs143947592, ClinGen CA10006359, ClinVar RCV002862365, ClinVar RCV004064980, REVEL 0.21, MetaLR 0.31, Uncertain significance, not specified; not provided
- A17T (p.Ala17Thr), gnomAD 21-33325104-G-A, REVEL 0.10, MetaLR 0.26
- A17A (p.Ala17Ala), gnomAD 21-33325106-G-T, CADD 10.40
- P18P (p.Pro18Pro), gnomAD 21-33325109-A-G, CADD 10.90
- W19C (p.Trp19Cys), TOPMed rs1332357638
- W19G (p.Trp19Gly), rs1227854358, ClinGen CA410105013, ClinVar RCV001876300, TOPMed rs1227854358, REVEL 0.35, MetaLR 0.40, Uncertain significance, not provided
- W19R (p.Trp19Arg), TOPMed rs1227854358, gnomAD rs1227854358, MetaLR 0.21, MetaSVM -0.90, Uncertain significance
- W19L (p.Trp19Leu), gnomAD 21-33325111-G-T, REVEL 0.48, MetaLR 0.46
- V20A (p.Val20Ala), NCI-TCGA Cosmic COSV5425, MetaLR 0.19, MetaSVM -0.99, Variant assessed as somatic; moderate impact.
- V20L (p.Val20Leu), NCI-TCGA TCGA novel, REVEL 0.10, MetaLR 0.31, Variant assessed as somatic; moderate impact.
- L21* (p.Leu21Ter), gnomAD 21-33325117-T-A, CADD 34.00
- S22A (p.Ser22Ala), rs1026279976, ClinGen CA320129915, ClinVar RCV003547199, Ensembl rs1026279976, Uncertain significance, not provided
- S22C (p.Ser22Cys), ExAC rs745384435, gnomAD rs745384435, REVEL 0.20, MetaLR 0.25
- S22F (p.Ser22Phe), ExAC rs745384435, gnomAD rs745384435, REVEL 0.12, MetaLR 0.24
- S22T (p.Ser22Thr), gnomAD 21-33325119-T-A, REVEL 0.07, MetaLR 0.23
- S22S (p.Ser22Ser), gnomAD 21-33325121-C-A, CADD 12.20
- A23T (p.Ala23Thr), TOPMed rs1219830561, gnomAD rs1219830561, REVEL 0.29, MetaLR 0.42
- A23V (p.Ala23Val), TOPMed rs893038815, MetaLR 0.27, MetaSVM -0.68
- A23P (p.Ala23Pro), gnomAD 21-33325122-G-C, REVEL 0.51, MetaLR 0.50
- A23E (p.Ala23Glu), gnomAD 21-33325123-C-A, REVEL 0.55, MetaLR 0.43
- A23A (p.Ala23Ala), gnomAD 21-33325124-A-C, CADD 13.80
- A24V (p.Ala24Val), rs779701967, UniProt VAR 084085, ExAC rs779701967, gnomAD rs779701967, REVEL 0.41, MetaLR 0.57, Benign
- p.Ala24 Ala25del, rs767512505, gnomAD 21-33325119-TCCGC, CADD 17.40
- A24D (p.Ala24Asp), gnomAD 21-33325126-C-A, REVEL 0.47, MetaLR 0.58
- A24A (p.Ala24Ala), rs1224314225, gnomAD 21-33325127-C-T, CADD 12.90
- A25T (p.Ala25Thr), gnomAD 21-33325128-G-A, REVEL 0.31, MetaLR 0.38
- A25A (p.Ala25Ala), gnomAD 21-33325130-A-G, CADD 23.80
- G26D (p.Gly26Asp), Ensembl rs2083225267, REVEL 0.36, MetaLR 0.45
- G26R (p.Gly26Arg), gnomAD 21-33325131-G-C, REVEL 0.53, MetaLR 0.55
- G26V (p.Gly26Val), gnomAD 21-33335524-G-T, REVEL 0.38, MetaLR 0.45
- G27A (p.Gly27Ala), TOPMed rs1308957116, MetaLR 0.37, MetaSVM -0.53
- G27R (p.Gly27Arg), NCI-TCGA TCGA novel, TOPMed rs1809048623, REVEL 0.27, MetaLR 0.59, Variant assessed as somatic; moderate impact.
- G27E (p.Gly27Glu), gnomAD 21-33335525-TG-T, CADD 22.90
- G27V (p.Gly27Val), gnomAD 21-33335527-G-T, REVEL 0.25, MetaLR 0.52
- K28R (p.Lys28Arg), gnomAD rs1302842958, REVEL 0.19, MetaLR 0.26
- K28E (p.Lys28Glu), gnomAD 21-33335529-A-G, REVEL 0.07, MetaLR 0.15
- K28Q (p.Lys28Gln), gnomAD 21-33335529-A-C, REVEL 0.17, MetaLR 0.29
- K28K (p.Lys28Lys), rs566759208, gnomAD 21-33335531-A-G, CADD 4.98
- N29S (p.Asn29Ser), rs2123668473, ClinGen CA410105919, ClinVar RCV001966532, Ensembl rs2123668473, Uncertain significance, not provided
- N29Y (p.Asn29Tyr), gnomAD rs1384168868, REVEL 0.16, MetaLR 0.44
- N29K (p.Asn29Lys), gnomAD 21-33335527-G-GA, CADD 22.20
- N29I (p.Asn29Ile), gnomAD 21-33335527-GA-G, CADD 18.30
- N29N (p.Asn29Asn), gnomAD 21-33335534-T-C, CADD 3.01
- L30I (p.Leu30Ile), NCI-TCGA Cosmic COSV5425, REVEL 0.32, MetaLR 0.53, Variant assessed as somatic; moderate impact.
- L30V (p.Leu30Val), TOPMed rs2083225413, gnomAD rs2083225413, REVEL 0.29, MetaLR 0.39
- L30Q (p.Leu30Gln), gnomAD 21-33335536-T-A, REVEL 0.49, MetaLR 0.59
- L30P (p.Leu30Pro), gnomAD 21-33335536-T-C, REVEL 0.54, MetaLR 0.61
- L30L (p.Leu30Leu), rs749695070, gnomAD 21-33335537-A-G, CADD 0.79
- K31N (p.Lys31Asn), rs774975020, ClinGen CA10006386, ClinVar RCV002649343, ClinVar RCV004927836, REVEL 0.22, MetaLR 0.48, Uncertain significance, not specified; not provided
- K31T (p.Lys31Thr), ExAC rs771153007, TOPMed rs771153007, gnomAD rs771153007, REVEL 0.14, MetaLR 0.36
- K31E (p.Lys31Glu), gnomAD 21-33335538-A-G, REVEL 0.06, MetaLR 0.28
- S32P (p.Ser32Pro), ExAC rs746333531, gnomAD rs746333531, REVEL 0.05, MetaLR 0.16
- S32C (p.Ser32Cys), gnomAD 21-33335542-C-G, REVEL 0.26, MetaLR 0.51
- S32S (p.Ser32Ser), rs1274652513, gnomAD 21-33335543-T-A, CADD 2.86
- P33H (p.Pro33His), NCI-TCGA Cosmic COSV5425, MetaLR 0.82, MetaSVM 0.81, Variant assessed as somatic; moderate impact.
- P33del (p.Pro33del), gnomAD 21-33335541-TCTC-, CADD 10.90
- P33S (p.Pro33Ser), gnomAD 21-33335544-C-T, REVEL 0.43, MetaLR 0.79
- P33P (p.Pro33Pro), gnomAD 21-33335546-T-C, CADD 7.69
- Q34* (p.Gln34Ter), rs367718640, ClinGen CA10006388, ClinVar RCV003852712, ESP rs367718640, CADD 33.00, Pathogenic
- Q34L (p.Gln34Leu), ExAC rs775701968, TOPMed rs775701968, gnomAD rs775701968, REVEL 0.27, MetaLR 0.43
- Q34P (p.Gln34Pro), ExAC rs775701968, TOPMed rs775701968, gnomAD rs775701968, REVEL 0.29, MetaLR 0.47
- Q34R (p.Gln34Arg), gnomAD 21-33335548-A-G, REVEL 0.25, MetaLR 0.37
- Q34H (p.Gln34His), gnomAD 21-33335549-A-C, REVEL 0.24, MetaLR 0.46
- Q34Q (p.Gln34Gln), rs2083225708, gnomAD 21-33335549-A-G, CADD 3.98
- V36L (p.Val36Leu), gnomAD rs2083225754, REVEL 0.28, MetaLR 0.35
- E37K (p.Glu37Lys), ExAC rs764413583, TOPMed rs764413583, gnomAD rs764413583, REVEL 0.13, MetaLR 0.24
- E37E (p.Glu37Glu), gnomAD 21-33335558-G-A, CADD 1.27
- V38F (p.Val38Phe), gnomAD 21-33335559-G-T, REVEL 0.41, MetaLR 0.44
- V38V (p.Val38Val), rs776948576, gnomAD 21-33335561-C-T, CADD 2.44
- D39N (p.Asp39Asn), rs148989381, ClinGen CA10006393, ClinVar RCV001303454, ClinVar RCV003963202, REVEL 0.10, MetaLR 0.10, Conflicting interpretations, not specified; not provided
- D39G (p.Asp39Gly), gnomAD 21-33335563-A-G, REVEL 0.21, MetaLR 0.24
- D39D (p.Asp39Asp), rs764918822, gnomAD 21-33335564-C-T, CADD 6.65
- I40V (p.Ile40Val), gnomAD rs1247129584, MetaLR 0.23, MetaSVM -0.93
- I41V (p.Ile41Val), gnomAD 21-33335568-A-G, REVEL 0.08, MetaLR 0.14
- I41T (p.Ile41Thr), gnomAD 21-33335569-T-C, REVEL 0.22, MetaLR 0.46
- D42G (p.Asp42Gly), TOPMed rs2083226005, REVEL 0.73, MetaLR 0.56
- D42N (p.Asp42Asn), Ensembl rs1601855670, MetaLR 0.26, MetaSVM -0.79
- D42Y (p.Asp42Tyr), gnomAD 21-33335571-G-T, REVEL 0.72, MetaLR 0.58
- D43G (p.Asp43Gly), rs143773564, ClinGen CA320140533, ClinVar RCV004096351, ESP rs143773564, REVEL 0.59, MetaLR 0.46, Uncertain significance, not specified
- D43N (p.Asp43Asn), TOPMed rs2083226033, gnomAD rs2083226033, REVEL 0.34, MetaLR 0.38
- N44D (p.Asn44Asp), 1000Genomes rs538755984, ExAC rs538755984, TOPMed rs538755984, gnomAD rs538755984, REVEL 0.07, MetaLR 0.24, Uncertain significance
- N44H (p.Asn44His), rs538755984, ClinGen CA10006395, ClinVar RCV001901707, ClinVar RCV004042624, REVEL 0.24, MetaLR 0.42, Uncertain significance, not specified; not provided
- N44S (p.Asn44Ser), rs139293982, ClinGen CA10006396, ClinVar RCV002016058, 1000Genomes rs139293982, REVEL 0.12, MetaLR 0.09, Uncertain significance, not provided
- N44T (p.Asn44Thr), rs139293982, ClinGen CA410106015, ClinVar RCV003120381, Likely risk allele, Susceptibility to severe COVID-19
- N44Y (p.Asn44Tyr), 1000Genomes rs538755984, ExAC rs538755984, TOPMed rs538755984, gnomAD rs538755984, REVEL 0.21, MetaLR 0.47, Uncertain significance
- N44N (p.Asn44Asn), rs765929924, gnomAD 21-33335579-C-T, CADD 5.59
- F45L (p.Phe45Leu), ExAC rs751075101, gnomAD rs751075101, REVEL 0.34, MetaLR 0.43
- F45F (p.Phe45Phe), gnomAD 21-33335582-T-C, CADD 3.36
- I46M (p.Ile46Met), gnomAD rs1407479349, REVEL 0.33, MetaLR 0.47, Uncertain significance, not specified
- I46F (p.Ile46Phe), gnomAD 21-33335583-A-T, REVEL 0.16, MetaLR 0.33
- I46S (p.Ile46Ser), gnomAD 21-33335584-T-G, REVEL 0.46, MetaLR 0.40
- W49R (p.Trp49Arg), gnomAD 21-33335592-T-A, REVEL 0.79, MetaLR 0.86
- N50D (p.Asn50Asp), gnomAD 21-33335595-A-G, REVEL 0.04, MetaLR 0.17
- N50N (p.Asn50Asn), rs1471220497, gnomAD 21-33335597-C-T, CADD 3.83
- N50K (p.Asn50Lys), gnomAD 21-33335597-C-A, REVEL 0.06, MetaLR 0.17
- R51G (p.Arg51Gly), TOPMed rs1354543562, gnomAD rs1354543562, REVEL 0.14, MetaLR 0.16
- R51S (p.Arg51Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- R51R (p.Arg51Arg), gnomAD 21-33335600-G-A, CADD 1.78
- S52N (p.Ser52Asn), 1000Genomes rs1318994012, gnomAD rs1318994012, REVEL 0.17, MetaLR 0.29
- S52T (p.Ser52Thr), NCI-TCGA Cosmic COSV9953, MetaLR 0.26, MetaSVM -1.01, Variant assessed as somatic; moderate impact.
- S52S (p.Ser52Ser), rs754447453, gnomAD 21-33335603-C-T, CADD 0.33
- D53N (p.Asp53Asn), rs377298705, ClinGen CA10006400, ClinVar RCV001919178, 1000Genomes rs377298705, REVEL 0.11, MetaLR 0.13, Uncertain significance, not provided
- D53Y (p.Asp53Tyr), 1000Genomes rs377298705, ExAC rs377298705, TOPMed rs377298705, gnomAD rs377298705, REVEL 0.22, MetaLR 0.21, Uncertain significance
- D53E (p.Asp53Glu), gnomAD 21-33335606-T-G, REVEL 0.11, MetaLR 0.10
- D53D (p.Asp53Asp), rs747735089, gnomAD 21-33335606-T-C, CADD 0.14
- E54D (p.Glu54Asp), gnomAD 21-33335609-G-T, REVEL 0.15, MetaLR 0.19
- S55F (p.Ser55Phe), ExAC rs757683855, gnomAD rs757683855, REVEL 0.14, MetaLR 0.27
- S55Y (p.Ser55Tyr), gnomAD 21-33335611-C-A, REVEL 0.29, MetaLR 0.42
- V56I (p.Val56Ile), TOPMed rs1218131188, gnomAD rs1218131188, REVEL 0.04, MetaLR 0.19
- V56A (p.Val56Ala), gnomAD 21-33335614-T-C, REVEL 0.13, MetaLR 0.26
- V56V (p.Val56Val), gnomAD 21-33335615-C-A, CADD 0.55
- G57R (p.Gly57Arg), rs201532160, ClinGen CA10006404, ClinVar RCV001940852, UniProt VAR 084086, REVEL 0.12, MetaLR 0.16, Uncertain significance, not provided
- G57E (p.Gly57Glu), gnomAD 21-33335617-G-A, REVEL 0.12, MetaLR 0.20
- G57G (p.Gly57Gly), rs2123668743, gnomAD 21-33335618-G-A, CADD 1.42
- N58D (p.Asn58Asp), TOPMed rs1206797104, gnomAD rs1206797104, REVEL 0.17, MetaLR 0.37
- N58K (p.Asn58Lys), gnomAD 21-33335621-T-G, REVEL 0.26, MetaLR 0.59
- V59L (p.Val59Leu), Ensembl rs2123668766, REVEL 0.25, MetaLR 0.26
- T60A (p.Thr60Ala), NCI-TCGA Cosmic COSV5425, MetaLR 0.57, MetaSVM 0.08, Variant assessed as somatic; moderate impact.
- T60P (p.Thr60Pro), gnomAD 21-33335625-A-C, REVEL 0.71, MetaLR 0.57
- T60N (p.Thr60Asn), gnomAD 21-33335626-C-A, REVEL 0.62, MetaLR 0.54
- T60T (p.Thr60Thr), gnomAD 21-33335627-T-C, CADD 3.51
- F61V (p.Phe61Val), rs2516859217, ClinGen CA410106167, ClinVar RCV002966804, Uncertain significance, not provided
- S62* (p.Ser62Ter), 1000Genomes rs542762423, ExAC rs542762423, gnomAD rs542762423, CADD 36.00
- S62F (p.Ser62Phe), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- S62P (p.Ser62Pro), gnomAD 21-33335631-T-C, REVEL 0.62, MetaLR 0.55
- S62L (p.Ser62Leu), gnomAD 21-33335632-C-T, REVEL 0.54, MetaLR 0.59
- S62S (p.Ser62Ser), gnomAD 21-33335633-A-G, CADD 7.39
- F63L (p.Phe63Leu), gnomAD 21-33335636-C-A, REVEL 0.11, MetaLR 0.15
- F63F (p.Phe63Phe), rs61735334, gnomAD 21-33335636-C-T, CADD 5.56
- D64N (p.Asp64Asn), rs142438988, ClinGen CA10006408, ClinVar RCV001915001, ClinVar RCV005584945, REVEL 0.25, MetaLR 0.46, Uncertain significance, not specified; not provided
Public IFNAR1 analysis runs
- IFNAR1 analysis run — IFNAR1 (819 variants) — completed 2026-08-19